Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H1 2018

  • ID: 4576066
  • Drug Pipelines
  • 61 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Elsalys Biotech SA
  • Ignyta Inc
  • Incyte Corp
  • MORE
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Tyrosine Protein Kinase Mer - Pipeline Review, H1 2018'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells.

It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

The report 'Tyrosine Protein Kinase Mer - Pipeline Review, H1 2018' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 11 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Solid Tumor, Glioblastoma Multiforme (GBM), Ovarian Cancer, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastric Cancer, Hematological Tumor, Metastatic Colorectal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Retinitis Pigmentosa (Retinitis).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Elsalys Biotech SA
  • Ignyta Inc
  • Incyte Corp
  • MORE
Introduction

Report Coverage

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Basilea Pharmaceutica Ltd

Celldex Therapeutics Inc

Celon Pharma SA

Dong-A Socio Holdings Co Ltd

Elsalys Biotech SA

Ignyta Inc

Incyte Corp

Ono Pharmaceutical Co Ltd

Qurient Co Ltd

SignalChem Lifesciences Corp

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-196969 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-241161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-4501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOPE-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-81776 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mer-590 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MRX-2843 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MRX-6313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MERTK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UNC-569 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Dec 29, 2017: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor

Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting

Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting

Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting

Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting

Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting

Mar 21, 2016: New Kinase Inhibitor Effective against Drug-Resistant Leukemia, Preclinical Study Finds

Mar 11, 2013: Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect

Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs

Jun 08, 2010: Graham’s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Pipeline by Celldex Therapeutics Inc, H1 2018

Pipeline by Celon Pharma SA, H1 2018

Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Pipeline by Elsalys Biotech SA, H1 2018

Pipeline by Ignyta Inc, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Pipeline by Qurient Co Ltd, H1 2018

Pipeline by SignalChem Lifesciences Corp, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Dong-A Socio Holdings Co Ltd
  • Elsalys Biotech SA
  • Ignyta Inc
  • Incyte Corp
  • Ono Pharmaceutical Co Ltd
  • Qurient Co Ltd
  • SignalChem Lifesciences Corp
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll